ALAMAR BIOSCIENCES INC (ALMR)
Health Care · Life Science Tools & Services · NASDAQ
Alamar Biosciences is a proteomics company providing a high-sensitivity platform for precise protein biomarker detection and analysis to drive medical research and future diagnostics.
What ALAMAR BIOSCIENCES INC does
Alamar Biosciences is a commercial-stage proteomics company that provides an integrated platform for the detection and analysis of protein biomarkers. Its proprietary NULISA technology enables ultra-sensitive detection of proteins in biological fluids like blood, supporting applications ranging from discovery and translational research to future diagnostics. The company's primary offering, the ARGO HT System, is supported by a suite of proprietary consumables and analytical software.
Themes: proteomics, biomarker discovery, precision medicine, in vitro diagnostics (IVD), life science tools
Fundamentals
- Price$25.91 as of 2026-10-08 close
- Market cap$1.8B as of 2026-07-31 (share count; price 2026-10-08)
- P/En/a earnings data not available
- Debt / equity1.32 as of 2026-09-03
- Beta-0.20 as of 2026-09-03
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How ALAMAR BIOSCIENCES INC looks technically
ALAMAR BIOSCIENCES INC (ALMR): a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-07-31, breaking below its recent trading range.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $31.24 | $31.24 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 37.76. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control | 28.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 38.0 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($25.37 to $39.61) — its "stochastic" reading is 4 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 3.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
7
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-07-31, breaking below its recent trading range | 1 session |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $39.61 (set on 2026-10-06) | $39.61 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $19.27 (set on 2026-06-09) | $19.27 |
| Above the all-time low | it is 34.5% above its all-time low | +34.5% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 72% of it) | 72nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.93 between its high and its low — about 11.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.93 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $25.97 and $37.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $25.97 – $31.87 – $37.78 |
| Typical daily range (% of price) | its price moves about 11.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 11.3% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.85× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Gap filled | a 2.6% gap up opened on 2026-08-19 has been "filled" 32 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 32 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -32.05% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.5 percentage points (the stock lost 13.5% while the market gained 1.0%) | -14.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.4 percentage points (the stock gained 2.4% while the market gained 3.8%) | -1.4% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 6 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 6 |
|---|---|---|
| Bearish technical signals | 4 of the 6 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 6 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -11.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid since 2026-04-17, so the typical buyer over that stretch is under water. That average is $27.88 — a volume-weighted average of daily closes over 111 sessions, not a true tick-by-tick VWAP. | -7.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-10 (its 8-K), so the typical buyer over that stretch is under water. That average is $32.38 — a volume-weighted average of daily closes over 43 sessions, not a true tick-by-tick VWAP. | -20.0% |
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $37.76.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 10 trading days, since 2026-09-25.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$35.40 range $31.00 – $45.00; median $34.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALMR
- Consensus EPS estimate-$0.2013 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 from -$0.2013, on 2026-09-07, 32-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on research use only (RUO) market with future IVD regulatory hurdles","History of operating losses and potential need for additional capital","Highly competitive and rapidly evolving proteomics technology landscape"]
What changed in the latest 10-Q
AI-assisted comparison of ALMR's 10-Q filed 2026-08-11 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-11) states that 52% of sales revenue was generated from academic institutions, 42% from biopharmaceutical companies, and 6% from distributors for the three months ended June 30, 2026.
- Newer filing (2026-08-11) states that for the three months ended June 30, 2026, 69% of sales were from the Americas region, 22% from EMEA, and 9% from APAC.
- Newer filing (2026-08-11) reports net losses of $13.2 million and $7.0 million for the three months ended June 30, 2026 and 2025, respectively.
- Newer filing (2026-08-11) reports an accumulated deficit of $203.3 million and unrestricted cash, cash equivalents and short-term investments of $250.1 million as of June 30, 2026.
- Newer filing (2026-08-11) includes "Middle East" in the list of regions covered by distribution agreements.
- Removed:
- Older filing (2026-05-08) stated that 56% of sales revenue was generated from academic institutions, 39% from biopharmaceutical companies, and 4% from distributors for the three months ended March 31, 2026.
- Older filing (2026-05-08) stated that for the three months ended March 31, 2026, 62% of sales were from the Americas region, 29% from EMEA, and 9% from APAC.
- Older filing (2026-05-08) reported net losses of $21.3 million and $7.7 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-08) reported an accumulated deficit of $190.1 million and unrestricted cash and cash equivalents of $64.6 million as of March 31, 2026.
- Older filing (2026-05-08) described collaborations as "multiple multi-million dollar collaborations" with research foundations.
- Older filing (2026-05-08) did not include "Middle East" in the list of regions covered by distribution agreements.
- Reworded:
- Newer filing (2026-08-11) refers to "our subsidiaries" while older filing (2026-05-08) refers to "its subsidiary".
- Newer filing (2026-08-11) removed "(the "Securities Act")" after "Securities Act of 1933, as amended" and changed "the Company's Registration Statement" to "our Registration Statement".
- Newer filing (2026-08-11) removed "multi-million dollar" from the description of collaborations with research foundations.
- Newer filing (2026-08-11) changed "unrestricted cash and cash equivalents" (older, 2026-05-08) to "unrestricted cash, cash equivalents and short-term investments".
- Period references changed from three months ended March 31, 2026 (older) to three months ended June 30, 2026 (newer).
- Notes:
- Newer filing text is truncated at the end of the 'Key business metrics' section and does not include subsequent sections, so changes beyond that point cannot be assessed.
- Both filings appear truncated at the same structural point; comparison is limited to the provided text.
Risk Factors
- Reworded:
- In the newer filing (2026-08-11), the loss figures were updated to net losses of $13.2 million and $34.5 million for the three and six months ended June 30, 2026, respectively. In the older filing (2026-05-08), the figures were net losses of $21.3 million and $7.7 million for the three months ended March 31, 2026 and 2025, respectively.
- In the newer filing (2026-08-11), the accumulated deficit as of June 30, 2026 was approximately $203.3 million. In the older filing (2026-05-08), the accumulated deficit as of March 31, 2026 was approximately $190.1 million.
- Notes:
- The provided excerpts of both filings appear truncated at the same point in the text (mid-sentence under the legal proceedings risk factor), so only the visible portions could be compared.
- Only the Risk Factors section text provided was compared; page numbers (37 vs. 32) reflect formatting and are not substantive content changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-042 buys ($8M) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-04-20. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALMR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ALMR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 3,474,828
- Reported value $94,133,090
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ALMR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ALMR had 2,122,340 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ALMR had 3.06% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.95 days to cover at the same settlement.
- Reported short interest (shares) 2,122,340
- Short interest (% of shares outstanding) 3.06%
- Prior settlement (shares) 2,121,181
- Reported change 0.05%
- Days to cover (reported) 7.95
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Olink (acquired by Thermo Fisher Scientific)
- SomaLogic (acquired by Standard BioTools)
- Quanterix (QTRX)
- Seer (SEER)
- Bio-Rad Laboratories (BIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALMR vs…
ALAMAR BIOSCIENCES INC is found in…
Frequently asked questions
What does ALAMAR BIOSCIENCES INC (ALMR) do?
Alamar Biosciences is a commercial-stage proteomics company that provides an integrated platform for the detection and analysis of protein biomarkers. Its proprietary NULISA technology enables ultra-sensitive detection of proteins in biological fluids like blood, supporting applications ranging from discovery and translational research to future diagnostics. The company's primary offering, the ARGO HT System, is supported by a suite of proprietary consumables and analytical software.
What sector is ALAMAR BIOSCIENCES INC (ALMR) in?
ALAMAR BIOSCIENCES INC (ALMR) is classified in the Health Care sector. Its industry is Life Science Tools & Services. It trades on NASDAQ.
Who are ALAMAR BIOSCIENCES INC's (ALMR) competitors?
Notable peers of ALAMAR BIOSCIENCES INC (ALMR) include Olink (acquired by Thermo Fisher Scientific), SomaLogic (acquired by Standard BioTools), Quanterix, Seer and Bio-Rad Laboratories. This peer set is informational only — not financial advice.
Is ALAMAR BIOSCIENCES INC (ALMR) overbought or oversold right now?
ALAMAR BIOSCIENCES INC (ALMR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALMR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.